Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; referred to as “Shionogi”) has revealed that Pixie Dust Technologies, Inc. (Head Office: Tokyo, Japan; Representative…
Bio-Techne Corporation (NASDAQ: TECH) has released its financial results for the second quarter ending December 31, 2023. Key Highlights for the Second Quarter of Fiscal Year 2024: Bio-Techne’s financial statements…
Bio-Techne Corporation (NASDAQ: TECH) has unveiled a groundbreaking achievement, as its spatial biology brand, Advanced Cell Diagnostics (ACD), sets a new industry standard. The innovation comes in the form of…
Teva Announces Plan to Sell its Active-Pharmaceutical Ingredient (API) Business, ‘TAPI,’ as a Strategic Move Towards Growth Teva disclosed today its decision to divest its active-pharmaceutical ingredient (API) business, known…
Grifols, a distinguished global healthcare company with a 115-year legacy as a leading manufacturer of plasma-derived medicines, has bolstered its senior management team through two strategic appointments. Dr. Roland Wandeler…
Enhanced Precautions and Vigilance for Avian Influenza during Lunar New Year Celebrations in Asia As preparations for Lunar New Year festivities in Asia gain momentum, the increased trading and handling…
In anticipation of World Cancer Day, the International Agency for Research on Cancer (IARC), the cancer agency of the World Health Organization (WHO), has unveiled the latest global cancer burden…
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, and Pierre Fabre…
ROHTO Pharmaceutical Strengthens Global Presence with EMA Aesthetics Through Strategic Partnership EMA Aesthetics, a Dublin-based global aesthetics company, has announced a significant strategic and equity collaboration with ROHTO Pharmaceutical, a…
Vivet Therapeutics Secures EUR 4.9 Million Government Funding for Gene Therapy Advancement in Cerebrotendinous Xanthomatosis Treatment” Vivet Therapeutics, a biotech company specializing in gene therapies for rare inherited metabolic disorders,…
Merck Unveils First Digital Hub in Singapore, a Landmark Move Beyond the US and Europe In a strategic move, Merck, a leading science and technology company, has inaugurated its inaugural…
E. Merck KG Announces Results of Board Election E. Merck KG, the entity holding approximately 70 percent of Merck KGaA on behalf of the Merck family, revealed the outcomes of…